Obalon Therapeutics, Inc.
OBLN · NASDAQ
12/31/2024 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $8,006 | $1,588 | $3,281 | $9,101 |
| % Growth | 404.2% | -51.6% | -63.9% | – |
| Cost of Goods Sold | $2,949 | $1,004 | $2,950 | $5,423 |
| Gross Profit | $5,057 | $584 | $331 | $3,678 |
| % Margin | 63.2% | 36.8% | 10.1% | 40.4% |
| R&D Expenses | $1,803 | $2,450 | $6,893 | $10,697 |
| G&A Expenses | $6,931 | $8,776 | $16,668 | $29,946 |
| SG&A Expenses | $9,922 | $8,776 | $16,668 | $29,946 |
| Sales & Mktg Exp. | $2,991 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11,725 | $11,226 | $23,561 | $40,643 |
| Operating Income | -$6,668 | -$10,642 | -$23,230 | -$36,965 |
| % Margin | -83.3% | -670.2% | -708% | -406.2% |
| Other Income/Exp. Net | -$423 | -$1,692 | -$446 | -$415 |
| Pre-Tax Income | -$7,091 | -$12,334 | -$23,676 | -$37,380 |
| Tax Expense | $39 | $0 | $0 | $0 |
| Net Income | -$7,130 | -$12,334 | -$23,676 | -$37,380 |
| % Margin | -89.1% | -776.7% | -721.6% | -410.7% |
| EPS | -13.83 | -1.59 | -5.03 | -19.64 |
| % Growth | -769.8% | 68.4% | 74.4% | – |
| EPS Diluted | -13.83 | -1.59 | -5.03 | -19.64 |
| Weighted Avg Shares Out | 516 | 7,771 | 4,707 | 1,904 |
| Weighted Avg Shares Out Dil | 516 | 7,771 | 4,707 | 1,904 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $843 | $894 | $581 |
| EBITDA | -$6,668 | -$11,491 | -$22,782 | -$36,799 |
| % Margin | -83.3% | -723.6% | -694.4% | -404.3% |